Infant hospitalisation with clinically confirmed RSV disease · pregnant women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intrauterine growth restriction · pregnant women
Respiratory syncytial virus vaccine showed no clear difference in intrauterine growth restriction compared with placebo (moderate certainty).
1 finding from 1 review
Stillbirth · pregnant women
Respiratory syncytial virus vaccine showed no clear difference in stillbirth compared with placebo (low certainty).
1 finding from 1 review
Maternal death · pregnant women
Respiratory syncytial virus vaccine showed no clear difference in maternal death compared with placebo (low certainty).
1 finding from 1 review
Preterm birth · pregnant women
It is very uncertain whether respiratory syncytial virus vaccine changes preterm birth compared with placebo (very low certainty).
1 finding from 1 review
Congenital abnormalities · pregnant women
Respiratory syncytial virus vaccine showed no clear difference in congenital abnormalities compared with placebo (high certainty).
1 finding from 1 review
Death before 1 year of age · pregnant women
It is very uncertain whether respiratory syncytial virus vaccine changes infant death compared with placebo (very low certainty).
1 finding from 1 review
Incidence of acute URTIs during the study period (the number of acute URTIs over a period of time) · children up to the age of 7 at risk of upper respiratory tract infection
Summary of findings table ‐ Vitamin A supplements showed no clear difference in incidence of acute URTIs during the study period (the number of… compared with placebo (low certainty).
1 finding from 1 review
Incidence of acute URTIs during the study period (proportion of participants with an acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Adverse events · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Severity of subjective symptoms (mean duration of acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Time to occurrence of acute URTI ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of cases with complications ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of hospitalisation ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of pain · children with acute postoperative pain
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · children with acute postoperative pain
2 findings from 1 review
Adverse events (reported in the first 7 days after the procedure) · children with acute postoperative pain
Ibuprofen showed no clear difference in adverse events (reported in the first 7 days after the procedure) compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (all causes) · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors leads to lower all‐cause death median compared with placebo (high certainty).
3P‐MACE median · people with diabetes and CKD
Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors probably leads to lower 3P‐MACE median compared with placebo (moderate certainty).
1 finding from 1 review